PharmaMar

aplidium albicans

Research

Cancer drug outperforms remdesivir in COVID-19 models

A new study found PharmaMar’s myeloma drug plitidepsin was almost 30 times more potent against SARS-CoV-2 than remdesivir in lab cells.

Angus Liu Jan 27, 2021 8:40am

Lungs illustration Image Pixabay

PharmaMar, Jazz get FDA priority review for lung cancer drug

Feb 18, 2020 8:48am

FDA Building 2

PharmaMar files for FDA approval of small cell lung cancer drug

Dec 17, 2019 8:36am